Product Description
Mechanisms of Action: BZD Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Estonia | Finland | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Lithuania | Luxembourg | Malaysia | Malta | Netherlands | New Zealand | Norway | Pakistan | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|